Our technology

ANGANY introduces a new approach to the treatment of allergic asthma. Its technology is the result of over 30 years of R&D in biotechnology, immunology and immunotherapeutics. ANGANY’s innovative approach is based on its proprietary eBioparticle™. This restores immune tolerance to a given allergen. In this way, the allergy at the source of allergic asthma can be countered in a targeted way.

ANGANY scientists have developed a new therapeutic approach tackling the source of allergic asthma, a serious complication of allergy. This innovative approach reverses the immune response to a given allergen in a targeted way and restores tolerance in a long-lasting manner.

Allergy sufferers experience an hypersensitivity reaction when exposed to certain protein components in their environment. These may be pollen proteins, dust mites or animal dander. Their immune systems become sensitized, programmed and ready to respond to any contact with these allergens, with harmful consequences. While these common natural components are allergens for allergy sufferers, the same components provoke no “reaction” in non-allergy sufferers. These foreign substances are simply broken down by metabolic processes or eliminated without producing any symptoms. Why the immune system of allergy sufferers reacts to common proteins in this way is the subject of numerous and complex studies. More about this is being discovered every day.

What we do know is that presenting the same allergen to an allergic person’s immune system, but in a different structure and by a different route, can modify their response and establish protection.

ANGANY has been able to engineer and produce allergen-carrying bioparticles that present allergens in a 3D structure that triggers a protective immune response rather than throught hypersensitivity. ANGANY’s bioparticles are synthesized using its 3rd generation plant-based production system. These bioparticles contain specific membrane lipids that confer self-adjuvanting qualities.

ANGANY has developed and operates an innovative 3rd generation plant production platform. This production system, based on plant transfection and transient expression, enables the efficient production of high-quality (“natural-like”) allergens and other sophisticated proteins for pharmaceutical use. ANGANY’s biologics are manufactured in a single step (1 week turnaround). This production platform is flexible and responsive, easy to scale-up, cost-effective and GMP-compliant. It is also safe and environmentally friendly.